Drug Trial Radar · NCT01143181
Study to Assess Brincidofovir Treatment of Serious Diseases or Conditions Caused by Double-stranded DNA Viruses
Last checked: Nov 19, 2026Latest source record: Aug 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
210
Actual
Start
Dec 2010
Primary completion
Dec 2012
Study completion Dec 2012
Sponsor
- Lead sponsor
- Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
- Sponsor type
- Industry
- First posted
- Jun 14, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a multicenter, open-label study of oral brincidofovir (BCV) treatment of serious disease or conditions caused by double-stranded DNA (dsDNA) virus(es). Subjects received either a weight-based or a fixed dose of oral BCV once weekly (QW) or twice weekly (BIW) for up to 3 months until clinical disease was resolved or stabilized and/or viral DNA by polymerase chain reaction testing was negative for 4 consecutive weeks, whichever was longer. Under the first protocol amendment, adults and adolescents (≥13 years) received 200 mg or 300 mg BCV BIW (not to exceed 4 mg/kg total weekly dose) depending on the difficulty of treating their disease (i.e., Group 1 or Group 2, respectively), and pediatric subjects (≤12 years) received 4 mg/kg BCV BIW. Under the second protocol amendment, adults and adolescents (≥13 years), regardless of viral infection/disease, had a maximum weekly dose of 200 mg, i.e., 200 mg QW or 100 mg BIW; not to exceed 4mg/kg total weekly dose. Pediatric subjects (≤12 years), regardless of viral infection/disease, had a maximum weekly dose of 4 mg/kg, i.e., 4 mg/kg QW or 2 mg/kg BIW; not to exceed 200 mg.
Conditions
- Double-stranded DNA Virus
Interventions
BrincidofovirDrug
Brincidofovir (BCV) was administered orally either once or twice weekly for up to 3 months. Treatment may have been extended for an additional 3 months depending a satisfactory review of safety parameters. Subjects could not receive more than a total of 6 months of treatment with BCV without prior approval.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects Who Had a Sustained and Significant Reduction in Plasma Viral Load of Primary dsDNA VirusTime frame: 3 months
Locations
37 sites in 1 country. Site status is shown where the registry gives one.
Loma Linda University Hospital
Loma Linda, California
Children's Hospital of LA
Los Angeles, California
UCLA Department of Medicine
Los Angeles, California
CHOC Children's
Orange, California
Univeristy of San Francisco
San Francisco, California
Lucile Packard Children's Hospital
Stanford, California
Children's Hospital of Colorado
Aurora, Colorado
Children's National Medical Center
Washington D.C., District of Columbia
University of Chicago
Chicago, Illinois
University of Iowa
Iowa City, Iowa
Childrens Hospital LSU
New Orleans, Louisiana
NIH
Bethesda, Maryland
Tufts Medical Center
Boston, Massachusetts
Brigham and Womens Hospital
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
University of Minnesota
Minneapolis, Minnesota
St. Louis Children's Hospital
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Hackensack University Medical Center
Hackensack, New Jersey
Mt. Sinai
New York, New York
Columbia University
New York, New York
Memorial Sloan Kettering Cancer Institute
New York, New York
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Levine Children's Hospital Carolina Medical Center
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
Cincinnati Childrens Hospital
Cincinnati, Ohio
Cleveland Clinic
Cleveland, Ohio
Nationwide Children's Hospital
Columbus, Ohio
Oregon Health and Science University
Portland, Oregon
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
UPMC
Pittsburgh, Pennsylvania
Childrens Hospital of Pittsburgh
Pittsburgh, Pennsylvania
Cook Children's Medical Center
Fort Worth, Texas
UT MD Anderson Cancer Center
Houston, Texas
Intermountain BMT program LDS Hospital
Salt Lake City, Utah
University of Washington-Fred Hutchinson Cancer Center
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.